Virax Biolabs Group (Virax Biolabs Group) EV-to-EBIT : 0.47 (As of Apr. 26, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Virax Biolabs Group's Enterprise Value is $-3.27 Mil. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.90 Mil. Therefore, Virax Biolabs Group's EV-to-EBIT for today is 0.47.

The historical rank and industry rank for Virax Biolabs Group's EV-to-EBIT or its related term are showing as below:

VRAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -192.84 Med: 0.16 Max: 1.47
Current: 0.49

During the past 4 years, the highest EV-to-EBIT of Virax Biolabs Group was 1.47. The lowest was -192.84. And the median was 0.16.

VRAX's EV-to-EBIT is ranked better than
77.83% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs VRAX: 0.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Virax Biolabs Group's Enterprise Value for the quarter that ended in Sep. 2023 was $0.73 Mil. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.90 Mil. Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -939.68%.

Virax Biolabs Group EV-to-EBIT Historical Data

The historical data trend for Virax Biolabs Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group EV-to-EBIT Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

-0.25

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-0.25	-

Competitive Comparison of Virax Biolabs Group's EV-to-EBIT

For the Biotechnology subindustry, Virax Biolabs Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's EV-to-EBIT falls into.

Virax Biolabs Group EV-to-EBIT Calculation

Virax Biolabs Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-3.273	/	-6.902
	=	0.47

Virax Biolabs Group's current Enterprise Value is $-3.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.90 Mil.

Virax Biolabs Group (NAS:VRAX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-6.902	/	0.734505
	=	-939.68 %

Virax Biolabs Group's Enterprise Value for the quarter that ended in Sep. 2023 was $0.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.90 Mil.

Virax Biolabs Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.